Since its foundation, Tillotts has been committed to improving care for people with gastrointestinal (GI) diseases. We collaborate with healthcare professionals and GI-experts to develop and market medicines for the treatment of diseases of the digestive system.
Our specific focus on the digestive system means we have in-depth knowledge of the challenges that gastroenterologists and hepatologists face on a daily basis. It also helps us look for innovative ways to improve care and quality of life for the 5–6 million people who live with inflammatory bowel diseases worldwide1.
1. Kaplan, G. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720-7